Cara M. Cassino
Net Worth
Last updated:
What is Cara M. Cassino net worth?
The estimated net worth of Dr. Cara M. Cassino is at least $7,065,200 as of 25 Jul 2017. He has received compensation worth at least $7,065,200 in ContraFect Corporation.
What is the salary of Cara M. Cassino?
Dr. Cara M. Cassino salary is $883,150 per year as Chief Medical Officer and Executive Vice President of R&D in ContraFect Corporation.
How old is Cara M. Cassino?
Dr. Cara M. Cassino is 63 years old, born in 1962.
What stocks does Cara M. Cassino currently own?
As insider, Dr. Cara M. Cassino owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| ContraFect Corporation (CFRX) | Chief Medical Officer and Executive Vice President of R&D | 4,000 | $0 | $0 |
What does ContraFect Corporation do?
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
Cara M. Cassino insider trading
ContraFect key executives
ContraFect Corporation executives and other stock owners filed with the SEC:
- Dr. Cara M. Cassino (63) Chief Medical Officer and Executive Vice President of R&D
- Dr. Roger James Pomerantz F.A.C.P., FACP, M.D. (68) Chairman, Chief Executive Officer & Pres
- Mr. Michael Messinger CPA, CPA (50) Chief Financial Officer